Zymeworks (ZYME) Return on Capital Employed (2022 - 2026)
Zymeworks' (ZYME) quarterly Return on Capital Employed came in at 30.28% in Q1 2026, up 267.0% year-on-year from 8.25% in Q1 2025, and down 7.81% quarter-over-quarter from 28.08% in Q4 2025.
Zymeworks (ZYME) Return on Capital Employed (2022 - 2026) Analysis & Trends
Zymeworks has disclosed Return on Capital Employed across 5 years of filings, most recently posting 30.28% for Q1 2026.
- Return on Capital Employed for Q1 2026 came in at 30.28%, up 267.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 30.28% (up 267.0% YoY), and the FY2025 annual result was 25.53%, up 608.0% from the prior year.
- Return on Capital Employed came in at 30.28% for Q1 2026 at Zymeworks, down from 28.08% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 40.44% in Q3 2023 to a low of 35.44% in Q4 2024.
- The 5-year median for Return on Capital Employed is 27.5% (2023), against an average of 10.18%.
- Across the five-year window, Return on Capital Employed plunged 7357 bps in 2024 and surged 1356 bps in 2025, its largest moves.
- Zymeworks' Return on Capital Employed stood at 34.45% in 2022, then plunged by 178 bps to 26.92% in 2023, then sank by 32 bps to 35.44% in 2024, then gained by 21 bps to 28.08% in 2025, then dropped by 8 bps to 30.28% in 2026.
- The last three Return on Capital Employed figures came in at 30.28% (Q1 2026), 28.08% (Q4 2025), and 19.57% (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 450.31% |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 51.73% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -107.40% |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 21.10% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -50.43% |
| 10 | Zymeworks | 1.73 Bn | 1.36 Bn | - | -30.28% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -30.28% |
| Dec 31, 2025 | -28.08% |
| Sep 30, 2025 | -19.57% |
| Jun 30, 2025 | -21.85% |
| Mar 31, 2025 | -32.94% |
| Dec 31, 2024 | -35.44% |
| Sep 30, 2024 | -33.13% |
| Jun 30, 2024 | -28.61% |
| Mar 31, 2024 | -29.11% |
| Dec 31, 2023 | -26.92% |
| Sep 30, 2023 | 40.44% |
| Jun 30, 2023 | 36.95% |
| Mar 31, 2023 | 31.56% |
| Dec 31, 2022 | 34.45% |